Yasmine Kanaan to Breast Neoplasms
This is a "connection" page, showing publications Yasmine Kanaan has written about Breast Neoplasms.
Connection Strength
1.519
-
Copeland RL, Kanaan Y. New targets in triple-negative breast cancer. Nat Rev Cancer. 2021 12; 21(12):744.
Score: 0.370
-
Owrang M, Copeland RL, Ricks-Santi LJ, Gaskins M, Beyene D, Dewitty RL, Kanaan YM. Breast Cancer Prognosis for Young Patients. In Vivo. 2017 Jul-Aug; 31(4):661-668.
Score: 0.273
-
Kanaan YM, Das JR, Bakare O, Enwerem NM, Berhe S, Beyene D, Williams V, Zhou Y, Copeland RL. Biological evaluation of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone as an anti-breast cancer agent. Anticancer Res. 2009 Jan; 29(1):191-9.
Score: 0.151
-
Aloufi A, Aubee J, Vargas KM, Apprey V, Thompson K, Copeland R, Kanaan Y, Ricks-Santi L, Brim H, Abbas M. Vitamin D receptor polymorphisms and associated miRNAs in the development of breast cancer in African American women. Gene. 2024 Nov 15; 927:148695.
Score: 0.111
-
Kanaan Y, Kpenu E, Utley K, Adams-Campbell L, Dunston GM, Brody LC, Broome C. Inherited BRCA2 mutations in African Americans with breast and/or ovarian cancer: a study of familial and early onset cases. Hum Genet. 2003 Oct; 113(5):452-60.
Score: 0.104
-
Cheng X, Murthy SRK, Zhuang T, Ly L, Jones O, Basadonna G, Keidar M, Kanaan Y, Canady J. Canady Helios Cold Plasma Induces Breast Cancer Cell Death by Oxidation of Histone mRNA. Int J Mol Sci. 2021 Sep 03; 22(17).
Score: 0.091
-
Ren X, Ghassemi P, Kanaan YM, Naab T, Copeland RL, Dewitty RL, Kim I, Strobl JS, Agah M. Kernel-Based Microfluidic Constriction Assay for Tumor Sample Identification. ACS Sens. 2018 08 24; 3(8):1510-1521.
Score: 0.073
-
Naab TJ, Gautam A, Ricks-Santi L, Esnakula AK, Kanaan YM, DeWitty RL, Asgedom G, Makambi KH, Abawi M, Blancato JK. MYC amplification in subtypes of breast cancers in African American women. BMC Cancer. 2018 03 09; 18(1):274.
Score: 0.072
-
Ricks-Santi LJ, Barley B, Winchester D, Sultan D, McDonald J, Kanaan Y, Pearson-Fields A, Sutton AL, Sheppard V, Williams C. Affluence Does Not Influence Breast Cancer Outcomes in African American Women. J Health Care Poor Underserved. 2018; 29(1):509-529.
Score: 0.071
-
Ricks-Santi L, McDonald JT, Gold B, Dean M, Thompson N, Abbas M, Wilson B, Kanaan Y, Naab TJ, Dunston G. Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women. Ethn Dis. 2017; 27(2):169-178.
Score: 0.067
-
Ricks-Santi LJ, Nie J, Marian C, Ochs-Balcom HM, Trevisan M, Edge SB, Kanaan Y, Freudenheim JL, Shields PG. BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study. Genet Epidemiol. 2013 Jul; 37(5):504-11.
Score: 0.051
-
Yu W, Kanaan Y, Bae YK, Baed YK, Gabrielson E. Chromosomal changes in aggressive breast cancers with basal-like features. Cancer Genet Cytogenet. 2009 Aug; 193(1):29-37.
Score: 0.039
-
Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T, Garrett E, Parmigiani G, Broome C, Sukumar S. Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res. 2004 Mar 15; 10(6):2052-7.
Score: 0.027
-
Khan F, Esnakula A, Ricks-Santi LJ, Zafar R, Kanaan Y, Naab T. Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women. Pathol Res Pract. 2018 May; 214(5):673-678.
Score: 0.018